Street Fight: JPMorgan says buy Novavax, Ladenburg says sell after vaccine data

Shares of Novavax (NVAX) are on the rise on Wednesday after the company announced data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID-19 vaccine with and without Matrix-M adjuvant in healthy adults 18-59 years of age. Following the news,... To see the rest of the story go to (See Story Here):(

Sign Up

Get the InvestingChannel
Free e-Letter Today

Learn More

Independent market opinion, analysis and ideas - delivered every business day

Premium market opinions, analysis, and ideas - delivered every business day

Editor's Picks